S'abonner

Immunosuppression-Free Life after Pediatric Liver Transplant: A Case-Control Study from the Society of Pediatric Liver Transplant (SPLIT) Registry - 11/12/23

Doi : 10.1016/j.jpeds.2023.113744 
Simone Kortbeek, MD 1, Sarah G. Anderson, MSc 2, Estella M. Alonso, MD 3, Elizabeth B. Rand, MD 4, John Bucuvalas, MD 5, George V. Mazariegos, MD 6, Kathleen M. Campbell, MD 7, Steven J. Lobritto, MD 8, Amy G. Feldman, MD 9, Krupa R. Mysore, MD 10, Ravinder Anand, PhD 2, Nazia Selzner, MD, PhD 11, Vicky L. Ng, MD 12, 13,
on behalf of the

SPLIT Registry

1 Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Alberta Children's Hospital, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada 
2 The Emmes Corporation, Rockville, MD 
3 Division of Gastroenterology, Hepatology, and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL 
4 Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA 
5 Division of Pediatric Hepatology, Icahn School of Medicine at Mount Sinai, New York, NY 
6 Division of Transplantation Surgery, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA 
7 Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 
8 Division of Gastroenterology, Hepatology, and Nutrition, Columbia University Irving Medical Center, New York, NY 
9 Division of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO 
10 Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX 
11 Ajmera Transplant Center, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada 
12 Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada 
13 Transplant and Regenerative Medicine Centre, The Hospital for Sick Children, Toronto, Ontario, Canada 

Reprint requests: Vicky L. Ng, MD, FRCPC, Division of Gastroenterology, Hepatology, and Nutrition, University of Toronto, Medical Director, Pediatric Liver Transplantation Staff Physician, The Hospital for Sick Children, 555 University Ave, Toronto ON, Canada, M5G 1X8.Division of Gastroenterology, Hepatology, and NutritionUniversity of TorontoMedical DirectorPediatric Liver Transplantation Staff PhysicianThe Hospital for Sick Children555 University AveTorontoONM5G 1X8Canada

Abstract

Objective

To compare long-term outcomes of pediatric liver transplant (LT) recipients off immunosuppression (IS) with matched controls on IS using data from the Society of Pediatric Liver Transplant (SPLIT) registry.

Study design

This was a retrospective case-control study. SPLIT participants <18 years of age, ≥4 years after isolated LT, and off IS for ≥1 year (cases) were age- and sex-matched 1:2 to patients with the same primary diagnosis and post-LT follow-up duration (controls). Primary outcomes included retransplantation, allograft rejection, IS comorbidities, and prevalence of SPLIT-derived composite ideal outcome (c-IO) achieved at the end of the follow-up period. Differences were compared using multiple linear regression for continuous outcomes and logistic regression for dichotomous data.

Results

The study cohort was composed of 33 cases (42.4% male, 60.6% biliary atresia, median age at LT of 0.7 [P25, P75, 0.5, 1.6] years, median IS withdrawal time of 9 [P25, P75, 6, 12] years after LT) and 66 age- and sex-matched controls. No cases required retransplantation. Cases and controls had similar growth parameters, laboratory values, calculated glomerular filtration rates, rates of post-transplant lymphoproliferative disease, graft rejection, and attainment of c-IO.

Conclusions

No differences in allograft rejection rates, IS complications, or c-IO prevalence were seen between SPLIT patients off IS and age- and sex-matched controls remaining on IS. Discontinuation of IS most commonly occurred in the context of rigorously designed IS withdrawal trials. The available sample size was small, affecting generalizability to the broader pediatric LT population.

Le texte complet de cet article est disponible en PDF.

Keywords : health status, therapy, withdrawal, comorbidity

Abbreviations : cGFR, c-IO, IS, LT, PTLD, SPLIT


Plan


 This work was presented as an abstract at the Society of Pediatric Liver Transplant (SPLIT) 2022 Annual Meeting.


© 2023  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 264

Article 113744- janvier 2024 Retour au numéro
Article précédent Article précédent
  • Physical Fitness and Body Mass Index Status of Hong Kong Primary Schoolchildren across the COVID-19 Pandemic, before and after School Closure
  • Ka-man Yip, Sam W.S. Wong, Hung-kwan So, Winnie W.Y. Tso, Parco M.F. Siu, Ian C.K. Wong, Jason C. Yam, Mike Y.W. Kwan, Terry Y.S. Lum, Lobo H.T. Louie, Albert Lee, Wilfred H.S. Wong, Patrick Ip
| Article suivant Article suivant
  • Music Therapy During Basic Daily Care in Critically Ill Children: A Randomized Crossover Clinical Trial
  • Sophie Mounier, Gilles Cambonie, Julien Baleine, Manon Le Roux, Sophie Bringuier, Christophe Milési

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.